<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Hemosorption was included in combined treatment of 110 patients with atherosclerotic dyscirculatory <z:hpo ids='HP_0001298'>encephalopathy</z:hpo> combined with <z:e sem="disease" ids="C0010068" disease_type="Disease or Syndrome" abbrv="">coronary heart disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The effect was assessed on the basis of clinical improvement, psychological tests, blood <z:chebi fb="23" ids="18059">lipid</z:chebi> assays, compressed spectral EEG analysis and ultrasonic flowmetry of the carotid arteries </plain></SENT>
<SENT sid="2" pm="."><plain>The effectiveness of hemosorption was demonstrated at <z:hpo ids='HP_0000001'>all</z:hpo> stages of the disease, with the regression of general cerebral and focal neurologic symptoms preceding clinical remission of <z:e sem="disease" ids="C0010068" disease_type="Disease or Syndrome" abbrv="">coronary heart disease</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Hemosorption was shown to have good effects on blood <z:chebi fb="23" ids="18059">lipids</z:chebi>, cerebral circulation and EEG spectrograms </plain></SENT>
</text></document>